CetirHexal may be available in the countries listed below.
Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of CetirHexal in the following countries:
International Drug Name Search
Generic Name: diphtheria, haemophilus, pertussis, tetanus, and polio (dif THEER ee a, hem OFF il us, per TUS is, TET a nus, POE lee oh)
Brand Names: Pentacel
Diphtheria, haemophilus influenzae, pertussis, tetanus, and polio are serious diseases caused by bacteria.
Diphtheria causes a thick coating in the nose, throat, and airway. It can lead to breathing problems, paralysis, heart failure, or death.
Haemophilus influenzae can cause minor flu symptoms or it can cause more serious symptoms such as swelling around the throat, making it hard to swallow or breathe. Haemophilus influenzae can also cause swelling of the membranes around the brain and spinal cord (meningitis).
Pertussis (whooping cough) causes coughing so severe that it interferes with eating, drinking, or breathing. These spells can last for weeks and can lead to pneumonia, seizures (convulsions), brain damage, and death.
Tetanus (lockjaw) causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw so the victim cannot open the mouth or swallow. Tetanus leads to death in about 1 out of 10 cases.
Polio affects the central nervous system and spinal cord. It can cause muscle weakness and paralysis. Polio is a life-threatening condition because it can paralyze the muscles that help you breathe.
Diphtheria, haemophilus influenzae, pertussis, and polio are spread from person to person. Tetanus enters the body through a cut or wound.
The diphtheria, haemophilus influenzae, pertussis, tetanus, and polio vaccine is used to help prevent these diseases in children who are ages 6 weeks through 4 years (before the 5th birthday).
This vaccine works by exposing your child to a small dose of the bacteria or a protein from the bacteria, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.
Like any vaccine, the diphtheria, haemophilus influenzae, pertussis, tetanus, and polio vaccine may not provide protection from disease in every person.
The diphtheria, haemophilus influenzae, pertussis, tetanus, and polio vaccine is given in a series of shots. The first shot is usually given when the child is 2 months old. The booster shots are then given at 4 months, 6 months, and 15 to 18 months of age. Your child's individual booster schedule may be different from these guidelines. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.
Be sure your child receives all recommended doses of this vaccine. If your child does not receive the full series of vaccines, he or she may not be fully protected against the disease.
Your child can still receive a vaccine if he or she has a cold or fever. In the case of a more severe illness with a fever or any type of infection, wait until the child gets better before receiving this vaccine.
Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shots caused any side effects.
Becoming infected with diphtheria, haemophilus influenzae, pertussis, tetanus, or polio is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.
Your child may not be able to receive this vaccine if he or she has ever received a similar vaccine that caused any of the following within 48 hours:
a very high fever (over 104 degrees);
excessive crying for 3 hours or longer;
fainting or going into shock;
seizure (convulsions); or
Guillain-Barré syndrome (within 6 weeks after receiving a vaccine containing tetanus).
Before receiving this vaccine, tell the doctor if your child has:
a history of seizures;
a neurologic disorder or disease affecting the brain (or if this was a reaction to a previous vaccine);
if the child is using steroid medication or receiving cancer chemotherapy or radiation treatment; or
a weak immune system caused by disease, bone marrow transplant, or by using certain medicines or receiving cancer treatments.
Your child can still receive a vaccine if he or she has a cold or fever. In the case of a more severe illness with a fever or any type of infection, wait until the child gets better before receiving this vaccine.
This vaccine is given as an injection into a muscle. Your child will receive this injection in a doctor's office or other clinic setting.
The diphtheria, haemophilus influenzae, pertussis, tetanus, and polio vaccine is given in a series of shots. The first shot is usually given when the child is 2 months old. The booster shots are then given at 4 months, 6 months, and 15 to 18 months of age. Your child's individual booster schedule may be different from these guidelines. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.
Your doctor may recommend treating fever and pain with an aspirin-free pain reliever such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil, and others) when the shot is given and for the next 24 hours. Follow the label directions or your doctor's instructions about how much of this medicine to give your child.
Contact your doctor if you will miss a booster dose or if you get behind schedule. The next dose should be given as soon as possible. There is no need to start over.
Be sure your child receives all recommended doses of this vaccine. If your child does not receive the full series of vaccines, he or she may not be fully protected against the disease.
An overdose of this vaccine is unlikely to occur.
Follow your doctor's instructions about any restrictions on food, beverages, or activity after receiving the vaccine.
Becoming infected with diphtheria, haemophilus influenzae, pertussis, tetanus, or polio is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.
Call your doctor at once if the child has any of these serious side effects:
extreme drowsiness, fainting;
fussiness, irritability, crying for an hour or longer;
seizure (black-out or convulsions); or
high fever.
Less serious side effects may include:
redness, pain, tenderness, or swelling where the shot was given;
low fever;
mild fussiness or crying;
headache or tiredness;
joint pain, body aches;
loss of appetite; or
mild nausea, diarrhea, or vomiting.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Usual Pediatric Dose for Haemophilus influenzae Prophylaxis:
Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis
Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.
Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.
Usual Pediatric Dose for Poliomyelitis Prophylaxis:
Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis
Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.
Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.
Usual Pediatric Dose for Diphtheria Prophylaxis:
Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis
Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.
Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.
Usual Pediatric Dose for Pertussis Prophylaxis:
Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis
Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.
Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.
Usual Pediatric Dose for Tetanus Prophylaxis:
Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis
Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.
Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.
Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.
Also tell the doctor if your child has received drugs or treatments in the past 2 weeks that can weaken the immune system, including:
an oral, nasal, inhaled, or injectable steroid medicine;
medications to treat psoriasis, rheumatoid arthritis, or other autoimmune disorders, such as azathioprine (Imuran), efalizumab (Raptiva), etanercept (Enbrel), leflunomide (Arava), and others; or
medicines to treat or prevent organ transplant rejection, such as basiliximab (Simulect), cyclosporine (Sandimmune, Neoral, Gengraf), muromonab-CD3 (Orthoclone), mycophenolate mofetil (CellCept), sirolimus (Rapamune), or tacrolimus (Prograf).
If your child is using any of these drugs, this vaccine may not work as well.
This list is not complete and there may be other drugs that can affect this vaccine. Tell your doctor about all the prescription and over-the-counter medications your child has received. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your child's doctor.
Klorasüksinat may be available in the countries listed below.
Chloramphenicol succinate sodium (a derivative of Chloramphenicol) is reported as an ingredient of Klorasüksinat in the following countries:
International Drug Name Search
Gen-Baclofen may be available in the countries listed below.
Baclofen is reported as an ingredient of Gen-Baclofen in the following countries:
International Drug Name Search
Niflumic may be available in the countries listed below.
Niflumic Acid is reported as an ingredient of Niflumic in the following countries:
International Drug Name Search
Klenac may be available in the countries listed below.
Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Klenac in the following countries:
International Drug Name Search
Fiorance may be available in the countries listed below.
Ipriflavone is reported as an ingredient of Fiorance in the following countries:
International Drug Name Search
Reptor may be available in the countries listed below.
Ursodeoxycholic Acid is reported as an ingredient of Reptor in the following countries:
International Drug Name Search
Asiben may be available in the countries listed below.
Albendazole is reported as an ingredient of Asiben in the following countries:
International Drug Name Search
